GlaxoSmithKline ( GlaxoSmithKline )

GlaxoSmithKline

GlaxoSmithKline's picture

GlaxoSmithKline started operations on 1 January 2001 following the merger of GlaxoWellcome plc and SmithKline Beecham plc, but our combined histories go back much further than that. Find out about the many products and mergers that led to the GSK we know today.

GlaxoSmithKline press release, blog etc

02/15/2018 - 01:45 GSK receives European approval for expanded indication for Fluarix Tetra (Influenza Vaccine) for ages six months and older
02/14/2018 - 04:27 GSK submits landmark IMPACT data to European Medicines Agency to support expanded label for Trelegy Ellipta
02/08/2018 - 06:09 ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment
02/07/2018 - 08:32 ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir
02/07/2018 - 03:32 GSK delivers improvements in sales, margins and cash flow in 2017
02/07/2018 - 02:45 GSKs meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age
01/26/2018 - 02:03 GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma
01/26/2018 - 00:05 GSKs Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over
01/23/2018 - 01:29 GSK responds to the AMR Benchmark
12/14/2017 - 01:58 GSK submits regulatory application for single-dose tafenoquine for the treatment of Plasmodium vivax malaria to Australias Therapeutic Goods Administration
12/12/2017 - 11:50 GSK achieves approval for Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) for adults in the US
12/11/2017 - 12:47 GSK presents promising new data for priority BCMA asset from its emerging Oncology pipeline at 59th ASH meeting
12/06/2017 - 17:47 GSK welcomes launch of the UK Governments Life Sciences Sector Deal
12/06/2017 - 16:12 New data supports the safety and efficacy of GSKs Shingrix in preventing shingles in autologous haematopoietic stem cell transplant patients
11/30/2017 - 01:58 ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women
11/28/2017 - 09:43 GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria
11/27/2017 - 10:32 ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine
11/23/2017 - 03:50 GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta